Treatment of ankylosing spondylitis

İsmail SARI, (Dokuz Eylül Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, İzmir, Türkiye)
Mehmet Akif ÖZTÜRK, (Gazi Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, Ankara, Türkiye)
Nurullah AKKOÇ (Dokuz Eylül Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, İzmir, Türkiye)
Turkish Journal of Medical Sciences
4 0
Yıl: 2015 Cilt: 45 Sayı: 2 Sayfa Aralığı: 416 - 430 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Treatment of ankylosing spondylitis

Öz:
Abstract: Ankylosing spondylitis is a chronic, infammatory, rheumatic disease that can reduce the quality of life and increase the riskof disability and mortality. It also causes direct and indirect economic losses due to health expenses and as a result of workforce loss.Management of this disease consists of pharmacological and nonpharmacological modalities. Until recently, pharmacological treatmentoptions have been very limited. However, development of novel biological drugs revolutionized the management of this disease. The aimof this review article is to present an updated overview of the pharmacologic treatment of ankylosing spondylitis. Nonpharmacologicaltreatment modalities including physiotherapy and exercise are only briefy mentioned and surgical treatment is not discussed.
Anahtar Kelime:

Konular: Cerrahi
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Onen F, Akar S, Birlik M, Sari I, Khan MA, Gurler O, Ergor A, Manisali M, Akkoc N. Prevalence of ankylosing spondylitis and related spondyloarthritides in an urban area of Izmir, Turkey. J Rheumatol 2008; 35: 305–309.
  • 2. Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003; 23: 61–66.
  • 3. Braun J, Pincus T. Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 2002; 20: S16–22.
  • 4. Jacobs P, Bissonnette R, Guenther LC. Socioeconomic burden of immune-mediated infammatory diseases--focusing on work productivity and disability. J Rheumatol Suppl 2011; 88: 55–61.
  • 5. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis- -results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 2000; 27: 613– 622.
  • 6. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, Dougados M, Geher P, Inman RD, Khan MA et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442–452.
  • 7. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65: 316–320.
  • 8. Lavie F, Pavy S, Dernis E, Goupille P, Cantagrel A, Tebib J, Claudepierre P, Flipo RM, Le Loet X, Maillefert JF et al. Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine 2007; 74: 346–352.
  • 9. Pham T, Fautrel B, Dernis E, Goupille P, Guillemin F, Le Loet X, Ravaud P, Claudepierre P, Miceli-Richard C, de Bandt M et al. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine 2007; 74: 638–646.
  • 10. Sidiropoulos PI, Hatemi G, Song IH, Avouac J, Collantes E, Hamuryudan V, Herold M, Kvien TK, Mielants H, Mendoza JM et al. Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatology (Oxford) 2008; 47: 355–361.
  • 11. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos- Vargas R, Collantes-Estevez E, Dagfnrud H, Dijkmans B, Dougados M, Emery P et al. 2010 update of the ASAS/ EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70: 896–904.
  • 12. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modifcation of the New York criteria. Arthritis Rheum 1984; 27: 361–368.
  • 13. Elyan M, Khan MA. Te role of nonsteroidal anti-infammatory medications and exercise in the treatment of ankylosing spondylitis. Curr Rheumatol Rep 2006; 8: 255–259.
  • 14. Dagfnrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2008; CD002822.
  • 15. Boulos P, Dougados M, Macleod SM, Hunsche E. Pharmacological treatment of ankylosing spondylitis: a systematic review. Drugs 2005; 65: 2111–2127.
  • 16. Dougados M, Behier JM, Jolchine I, Calin A, van der Heijde D, Olivieri I, Zeidler H, Herman H. Efcacy of celecoxib, a cyclooxygenase 2-specifc inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinfammatory drug. Arthritis Rheum 2001; 44: 180–185.
  • 17. Dougados M, Gueguen A, Nakache JP, Velicitat P, Veys EM, Zeidler H, Calin A. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-infammatory drug trial. Rheumatology (Oxford) 1999; 38: 235–244.
  • 18. Escalas C, Trijau S, Dougados M. Evaluation of the treatment efect of NSAIDs/TNF blockers according to diferent domains in ankylosing spondylitis: results of a meta-analysis. Rheumatology (Oxford) 2010; 49: 1317–1325.
  • 19. van der Heijde D, Baraf HS, Ramos-Remus C, Calin A, Weaver AL, Schif M, James M, Markind JE, Reicin AS, Melian A et al. Evaluation of the efcacy of etoricoxib in ankylosing spondylitis: results of a ffy-two-week, randomized, controlled study. Arthritis Rheum 2005; 52: 1205–1215.
  • 20. Dougados M, Nguyen M, Caporal R, Legeais J, Bouxin-Sauzet A, Pellegri-Guegnault B, Gomeni C. Ximoprofen in ankylosing spondylitis. A double blind placebo controlled dose ranging study. Scand J Rheumatol 1994; 23: 243–248.
  • 21. Gossec L, van der Heijde D, Melian A, Krupa DA, James MK, Cavanaugh PF, Reicin AS, Dougados M. Efcacy of cyclo- oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 2005; 64: 1563–1567.
  • 22. Sydnes OA. Comparison of piroxicam with indomethacin in ankylosing spondylitis: a double-blind crossover trial. British J Clin Pract 1981; 35: 40–44.
  • 23. Sieper J, Klopsch T, Richter M, Kapelle A, Rudwaleit M, Schwank S, Regourd E, May M. Comparison of two diferent dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis 2008; 67: 323– 329.
  • 24. Barkhuizen A, Steinfeld S, Robbins J, West C, Coombs J, Zwillich S. Celecoxib is efcacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J Rheumatol 2006; 33: 1805–1812.
  • 25. Dougados M, Dijkmans B, Khan M, Maksymowych W, van der Linden S, Brandt J. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002; 61 (Suppl. 3): iii40–50.
  • 26. Toussirot E, Wendling D. Recent progress in ankylosing spondylitis treatment. Expert Opin Pharmacother 2003; 4: 1–12.
  • 27. Amor B, Dougados M, Listrat V, Menkes CJ, Roux H, Benhamou C, Blotman F, Pattin S, Paolaggi JB, Duquesnoy B et al. Are classifcation criteria for spondylarthropathy useful as diagnostic criteria? Rev Rhum Engl Ed 1995; 62: 10–15.
  • 28. Amor B, Dougados M, Khan MA. Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am 1995; 21: 117–128.
  • 29. Bird HA, Le Gallez P, Astbury C, Looi D, Wright V. A parallel group comparison of tenoxicam and piroxicam in patients with ankylosing spondylitis. Pharmatherapeutica 1986; 4: 457–462.
  • 30. Dougados M, Simon P, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, van der Heijde D. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 2011; 70: 249–251.
  • 31. Boersma JW. Retardation of ossifcation of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. Scand J Rheumatol 1976; 5: 60–64.
  • 32. Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, Zeidler H, Dougados M. Nonsteroidal antiinfammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005; 52: 1756–1765.
  • 33. Kroon F, Landewe R, Dougados M, van der Heijde D. Continuous NSAID use reverts the efects of infammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012; 71: 1623–1629.
  • 34. Poddubnyy D, van der Heijde D. Terapeutic controversies in spondyloarthritis: nonsteroidal anti-infammatory drugs. Rheum Dis Clin North Am 2012; 38: 601–611.
  • 35. US Food and Drugs Administration Center for Drug Evaluation and Research. Public Health Advisory - FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal Anti- Infammatory Drugs (NSAIDs). Silver Spring, MD, USA: FDA: 2005.
  • 36. European Medicines Agency. Press Release: European Medicines Agency Update on Non-Selective NSAIDs. London, UK: EMA; 2005.
  • 37. Song IH, Poddubnyy DA, Rudwaleit M, Sieper J. Benefts and risks of ankylosing spondylitis treatment with nonsteroidal antiinfammatory drugs. Arthritis Rheum 2008; 58: 929–938.
  • 38. National Institute for Health and Care Excellence. Adalimumab, Etanercept and Infiximab for Ankylosing Spondylitis. NICE Technology Appraisal Guidance 143 2010. London, UK: NICE; 2010.
  • 39. van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewe R, Rudwaleit M, Braun J, Assessment of SpondyloArthritis International Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70: 905–908.
  • 40. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520–1528.
  • 41. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092–1102.
  • 42. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoef A, Parlow JL, Boyce SW, Verburg KM. Complications of the COX-2 inhibitors parecoxib and valdecoxib afer cardiac surgery. N Engl J Med 2005; 352: 1081–1091.
  • 43. Solomon SD, McMurray JJ, Pfefer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071–1080.
  • 44. Bolten WW. Problem of the atherothrombotic potential of non-steroidal anti-infammatory drugs. Ann Rheum Dis 2006; 65: 7–13.
  • 45. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-infammatory drugs: nested case-control study. Lancet 2005; 365: 475–481.
  • 46. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368: 1771–1781.
  • 47. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Terapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364: 675– 684.
  • 48. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-infammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302–1308.
  • 49. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633–1644.
  • 50. Hermann M. Cardiovascular risk associated with nonsteroidal anti-infammatory drugs. Curr Rheumatol Rep 2009; 11: 31– 35.
  • 51. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369: 465–473.
  • 52. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Terapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 665–674.
  • 53. Lewis SC, Langman MJ, Laporte JR, Matthews JN, Rawlins MD, Wiholm BE. Dose-response relationships between individual nonaspirin nonsteroidal anti-infammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002; 54: 320–326.
  • 54. Ofman JJ, MacLean CH, Straus WL, Morton SC, Berger ML, Roth EA, Shekelle P. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinfammatory drugs. J Rheumatol 2002; 29: 804–812.
  • 55. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-infammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247–1255.
  • 56. Leandro G, Pilotto A, Franceschi M, Bertin T, Lichino E, Di Mario F. Prevention of acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials. Dig Dis Sci 2001; 46: 1924–1936.
  • 57. Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowan J. Te prevention of chronic NSAID induced upper gastrointestinal toxicity: a Cochrane collaboration metaanalysis of randomized controlled trials. J Rheumatol 2000; 27: 2203–2214.
  • 58. Cryer B. Nonsteroidal anti-infammatory drug gastrointestinal toxicity. Curr Opin Gastroenterol 2001; 17: 503–512.
  • 59. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 133–141.
  • 60. Bonner GF, Fakhri A, Vennamaneni SR. A long-term cohort study of nonsteroidal anti-infammatory drug use and disease activity in outpatients with infammatory bowel disease. Infamm Bowel Dis 2004; 10: 751–757.
  • 61. Akkoc N, van der Linden S, Khan MA. Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy. Best Pract Res Cl Rh 2006; 20: 539–557.
  • 62. Ferraz MB, Tugwell P, Goldsmith CH, Atra E. Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990; 17: 1482–1486.
  • 63. Chen J, Liu C. Is sulfasalazine efective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol 2006; 33: 722–731.
  • 64. Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Banares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond) 2000; 14: 340–343.
  • 65. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, Schlincker A, Bonilla G, Ruiz-Sancho D, Fonseca A, Gijon- Banos J, Martin-Mola E. Sulfasalazine reduces the number of fares of acute anterior uveitis over a one-year period. J Rheumatol 2003; 30: 1277–1279.
  • 66. Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K, Brandt J, Haibel H, Hammer M, Krause A et al. Efcacy of sulfasalazine in patients with infammatory back pain due to undiferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 2006; 65: 1147–1153.
  • 67. Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005; CD004800.
  • 68. Taylor HG, Beswick EJ, Dawes PT. Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment. Clin Rheumatol 1991; 10: 43–48.
  • 69. Altan L, Bingol U, Karakoc Y, Aydiner S, Yurtkuran M. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2001; 30: 255–259.
  • 70. Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M, Munoz-Valle JF, Gamez-Nava JI. Efcacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 2004; 31: 1568–1574.
  • 71. Roychowdhury B, Bintley-Bagot S, Bulgen DY, Tompson RN, Tunn EJ, Moots RJ. Is methotrexate efective in ankylosing spondylitis? Rheumatology (Oxford) 2002; 41: 1330–1332.
  • 72. Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2006; CD004524.
  • 73. Chen J, Veras MM, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2013; 2: CD004524.
  • 74. Biasi D, Carletto A, Caramaschi P, Pacor ML, Maleknia T, Bambara LM. Efcacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol 2000; 19: 114–117.
  • 75. Sampaio-Barros PD, Costallat LT, Bertolo MB, Neto JF, Samara AM. Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2000; 29: 160–162.
  • 76. Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, Sieper J. No efcacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 2007; 66: 419–421.
  • 77. Chen J. Is methotrexate efective for the treatment of ankylosing spondylitis? Nat Clin Pract Rheumat 2007; 3: 490–491.
  • 78. Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of lefunomide in active ankylosing spondylitis. Ann Rheum Dis 2005; 64: 124–126.
  • 79. van Denderen JC, van der Paardt M, Nurmohamed MT, de Ryck YM, Dijkmans BA, van der Horst-Bruinsma IE. Double blind, randomised, placebo controlled study of lefunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis 2005; 64: 1761–1764.
  • 80. Kirwan J, Edwards A, Huitfeldt B, Tompson P, Currey H. Te course of established ankylosing spondylitis and the efects of sulphasalazine over 3 years. Br J Rheumatol 1993; 32: 729–733.
  • 81. Braun J, Sieper J. Terapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF- alpha therapy and other novel approaches. Arthritis Res 2002; 4: 307–321.
  • 82. Spies CM, Burmester GR, Buttgereit F. Analyses of similarities and diferences in glucocorticoid therapy between rheumatoid arthritis and ankylosing spondylitis - a systematic comparison. Clin Exp Rheumatol 2009; 27: S152–158.
  • 83. Haibel H, Fendler C, Listing J, Callhof J, Braun J, Sieper J. Efcacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis 2014; 73: 243–246.
  • 84. Ejstrup L, Peters ND. Intravenous methylprednisolone pulse therapy in ankylosing spondylitis. Dan Med Bull 1985; 32: 231–233.
  • 85. Mintz G, Enriquez RD, Mercado U, Robles EJ, Jimenez FJ, Gutierrez G. Intravenous methylprednisolone pulse therapy in severe ankylosing spondylitis. Arthritis Rheum 1981; 24: 734–736.
  • 86. Richter MB, Woo P, Panayi GS, Trull A, Unger A, Shepherd P. Te efects of intravenous pulse methylprednisolone on immunological and infammatory processes in ankylosing spondylitis. Clin Exp Immunol 1983; 53: 51–59.
  • 87. Peters ND, Ejstrup L. Intravenous methylprednisolone pulse therapy in ankylosing spondylitis. Scand J Rheumatol 1992; 21: 134–138.
  • 88. Braun J, Bollow M, Seyrekbasan F, Haberle HJ, Eggens U, Mertz A, Distler A, Sieper J. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol 1996; 23: 659–664.
  • 89. Karabacakoglu A, Karakose S, Ozerbil OM, Odev K. Fluoroscopy-guided intraarticular corticosteroid injection into the sacroiliac joints in patients with ankylosing spondylitis. Acta Radiol 2002; 43: 425–427.
  • 90. Luukkainen R, Nissila M, Asikainen E, Sanila M, Lehtinen K, Alanaatu A, Kautiainen H. Periarticular corticosteroid treatment of the sacroiliac joint in patients with seronegative spondylarthropathy. Clin Exp Rheumatol 1999; 17: 88–90.
  • 91. Maugars Y, Mathis C, Berthelot JM, Charlier C, Prost A. Assessment of the efcacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. Br J Rheumatol 1996; 35: 767–770.
  • 92. Maugars Y, Mathis C, Vilon P, Prost A. Corticosteroid injection of the sacroiliac joint in patients with seronegative spondylarthropathy. Arthritis Rheum 1992; 35: 564–568.
  • 93. Gunaydin I, Pereira PL, Daikeler T, Mohren M, Trubenbach J, Schick F, Kanz L, Kotter I. Magnetic resonance imaging guided corticosteroid injection of the sacroiliac joints in patients with therapy resistant spondyloarthropathy: a pilot study. J Rheumatol 2000; 27: 424–428.
  • 94. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, Eggens U, Distler A, Sieper J. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499–505.
  • 95. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M et al. Treatment of active ankylosing spondylitis with infiximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187–1193.
  • 96. Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, Xu W, Visvanathan S, Baker D, Goldstein N et al. Efcacy and safety of infiximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 2008; 59: 1270–1278.
  • 97. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J. Efcacy and safety of infiximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 582–591.
  • 98. Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, Krause A, Schewe S, Schneider M, Sorensen H et al. Persistent clinical efcacy and safety of infiximab in ankylosing spondylitis afer 8 years--early clinical response predicts long- term outcome. Rheumatology (Oxford) 2011; 50: 1690–1699.
  • 99. Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis afer 3 years of continuous treatment with infiximab. Arthritis Res Ter 2005; 7: R439– 444.
  • 100. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, Gromnica-Ihle E, Haibel H, Schewe S, Schneider M et al. Safety and efcacy of readministration of infiximab afer longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol 2007; 34: 510–515.
  • 101. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infiximab. Clin Pharmacokinet 2007; 46: 645–660.
  • 102. Neef HC, Riebschleger MP, Adler J. Meta-analysis: rapid infiximab infusions are safe. Aliment Pharmacol Ter 2013; 38: 365–376.
  • 103. Keeling S, Oswald A, Russell AS, Maksymowych WP. Prospective observational analysis of the efcacy and safety of low-dose (3 mg/kg) infiximab in ankylosing spondylitis: 4-year followup. J Rheumatol 2006; 33: 558–561.
  • 104. Maksymowych WP, Jhangri GS, Lambert RG, Mallon C, Buenviaje H, Pedrycz E, Luongo R, Russell AS. Infiximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efcacy and safety. J Rheumatol 2002; 29: 959–965.
  • 105. Inman RD, Maksymowych WP, Group CS. A double-blind, placebo-controlled trial of low dose infiximab in ankylosing spondylitis. J Rheumatol 2010; 37: 1203–1210.
  • 106. Collantes-Estevez E, Munoz-Villanueva MC, Zarco P, Torre- Alonso JC, Gratacos J, Gonzalez C, Sanmarti R, Canete JD. Efectiveness of reducing infiximab dose interval in non- responder patients with refractory spondyloarthropathies. An open extension of a multicentre study. Rheumatology (Oxford) 2005; 44: 1555–1558.
  • 107. Breban M, Ravaud P, Claudepierre P, Baron G, Henry YD, Hudry C, Euller-Ziegler L, Pham T, Solau-Gervais E, Chary- Valckenaere I et al. Maintenance of infiximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 2008; 58: 88–97.
  • 108. Ternant D, Mulleman D, Lauferon F, Vignault C, Ducourau E, Wendling D, Goupille P, Paintaud G. Infuence of methotrexate on infiximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. Br J Clin Pharmacol 2012; 73: 55–65.
  • 109. Mulleman D, Lauferon F, Wendling D, Ternant D, Ducourau E, Paintaud G, Goupille P. Infiximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. Arthritis Res Ter 2011; 13: R82.
  • 110. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48: 1667–1675.
  • 111. Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmarti R, Sany J et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1594–1600.
  • 112. Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230–3236.
  • 113. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346: 1349–1356.
  • 114. Dougados M, Combe B, Braun J, Landewe R, Sibilia J, Cantagrel A, Feydy A, van der Heijde D, Leblanc V, Logeart I. A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis 2010; 69: 1430–1435.
  • 115. Braun J, Pavelka K, Ramos-Remus C, Dimic A, Vlahos B, Freundlich B, Koenig AS. Clinical efcacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. J Rheumatol 2012; 39: 836–840.
  • 116. Baraliakos X, Haibel H, Fritz C, Listing J, Heldmann F, Braun J, Sieper J. Long-term outcome of patients with active ankylosing spondylitis with etanercept - sustained efcacy and safety afer seven years. Arthritis Res Ter 2013; 15: R67.
  • 117. Braun J, McHugh N, Singh A, Wajdula JS, Sato R. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology (Oxford) 2007; 46: 999–1004.
  • 118. van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, Olivieri I, Raeman F, Settas L, Sieper J et al. Etanercept 50 mg once weekly is as efective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65: 1572–1577.
  • 119. Navarro-Sarabia F, Fernandez-Sueiro JL, Torre-Alonso JC, Gratacos J, Queiro R, Gonzalez C, Loza E, Linares L, Zarco P, Juanola X et al. High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). Rheumatology (Oxford) 2011; 50: 1828–1837.
  • 120. Brandt J, Listing J, Haibel H, Sorensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J. Long-term efcacy and safety of etanercept afer readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford) 2005; 44: 342–348.
  • 121. Dougados M, Braun J, Szanto S, Combe B, Elbaz M, Geher P, Tabut G, Leblanc V, Logeart I. Efcacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis 2011; 70: 799–804.
  • 122. Dougados M, Braun J, Szanto S, Combe B, Geher P, Leblanc V, Logeart I. Continuous efcacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open- label extension of the SPINE study. Rheumatology (Oxford) 2012; 51: 1687–1696.
  • 123. van der Heijde D, Kivitz A, Schif MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H et al. Efcacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 2136–2146.
  • 124. Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H, Braun J, Sieper J. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a ffy-two-week open- label trial. Arthritis Rheum 2006; 54: 678–681.
  • 125. Revicki DA, Luo MP, Wordsworth P, Wong RL, Chen N, Davis JC Jr. Adalimumab reduces pain, fatigue, and stifness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efcacy for ankylosing spondylitis (ATLAS). J Rheumatol 2008; 35: 1346– 1353.
  • 126. Rudwaleit M, Rodevand E, Holck P, Vanhoof J, Kron M, Kary S, Kupper H. Adalimumab efectively reduces the rate of anterior uveitis fares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009; 68: 696–701.
  • 127. Rudwaleit M, Claudepierre P, Kron M, Kary S, Wong R, Kupper H. Efectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis. Arthritis Res Ter 2010; 12: R43.
  • 128. van der Heijde D, Schif MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, Dijkmans BA, Mease PJ, Davis JC Jr. Adalimumab efectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009; 68: 922–929.
  • 129. Sieper J, van der Heijde D, Dougados M, Brown LS, Lavie F, Pangan AL. Early response to adalimumab predicts long- term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis 2012; 71: 700–706.
  • 130. Rudwaleit M, Olivieri I, Boki KA, Griep EN, Jarvinen P, Wong RL, Kron M, Kary S, Kupper H. Adalimumab is efective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion. Rheumatology (Oxford) 2009; 48: 551–557.
  • 131. van der Heijde D, Pangan AL, Schif MH, Braun J, Borofsky M, Torre J, Davis JC, Jr, Wong RL, Kupper H, Collantes E. Adalimumab efectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis 2008; 67: 1218–1221.
  • 132. Inman RD, Davis JC Jr, Heijde D, Diekman L, Sieper J, Kim SI, Mack M, Han J, Visvanathan S, Xu Z et al. Efcacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58: 3402–3412.
  • 133. Braun J, Deodhar A, Inman RD, van der Heijde D, Mack M, Xu S, Hsu B. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO- RAISE study. Ann Rheum Dis 2012; 71: 661–667.
  • 134. van der Heijde D, Braun J, Deodhar A, Inman RD, Xu S, Mack ME, Hsu B. Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE). Rheumatology (Oxford) 2013; 52: 321–325.
  • 135. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short- term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997; 337: 1029–1035.
  • 136. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W et al. Maintenance infiximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–1549.
  • 137. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti- tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323–333.
  • 138. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132: 52–65.
  • 139. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR et al. Infiximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462–2476.
  • 140. Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780–787.
  • 141. Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J. Diferences in the incidence of fares or new onset of infammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti- tumor necrosis factor alpha agents. Arthritis Rheum 2007; 57: 639–647.
  • 142. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infiximab and etanercept. Arthritis Rheum 2005; 52: 2447–2451.
  • 143. Sieper J, Koenig A, Baumgartner S, Wishneski C, Foehl J, Vlahos B, Freundlich B. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 2010; 69: 226–229.
  • 144. Maksymowych WP, Salonen D, Inman RD, Rahman P, Lambert RG. Low-dose infiximab (3 mg/kg) signifcantly reduces spinal infammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo- controlled study. J Rheumatol 2010; 37: 1728–1734.
  • 145. Baraliakos X, Davis J, Tsuji W, Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and afer therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 2005; 52: 1216–1223.
  • 146. Lambert RG, Salonen D, Rahman P, Inman RD, Wong RL, Einstein SG, Tomson GT, Beaulieu A, Choquette D, Maksymowych WP. Adalimumab signifcantly reduces both spinal and sacroiliac joint infammation in patients with ankylosing spondylitis: a multicenter, randomized, double- blind, placebo-controlled study. Arthritis Rheum 2007; 56: 4005–4014.
  • 147. Braun J, Baraliakos X, Hermann KG, van der Heijde D, Inman RD, Deodhar AA, Baratelle A, Xu S, Xu W, Hsu B. Golimumab reduces spinal infammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Ann Rheum Dis 2012; 71: 878–884.
  • 148. van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L, Lin SL, Tsuji W, Davis JC Jr. Radiographic progression of ankylosing spondylitis afer up to two years of treatment with etanercept. Arthritis Rheum 2008; 58: 1324–1331.
  • 149. van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, Xu W, Baker D, Goldstein N, Braun J. Radiographic fndings following two years of infiximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008; 58: 3063–3070.
  • 150. van der Heijde D, Salonen D, Weissman BN, Landewe R, Maksymowych WP, Kupper H, Ballal S, Gibson E, Wong R. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ter 2009; 11: R127.
  • 151. Lie E, van der Heijde D, Uhlig T, Mikkelsen K, Rodevand E, Koldingsnes W, Kaufmann C, Kvien TK. Efectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis 2011; 70: 157–163.
  • 152. Haberhauer G, Strehblow C, Fasching P. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis. Wien Med Wochenschr 2010; 160: 220–224.
  • 153. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, Sieper J. Diferent response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010; 62: 1290–1297.
  • 154. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Haug- Rost I, Braun J, Sieper J. One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re- treated in case of a fare. Ann Rheum Dis 2013; 72: 305–306.
  • 155. Sieper J, Porter-Brown B, Tompson L, Harari O, Dougados M. Assessment of short-term symptomatic efcacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo- controlled trials. Ann Rheum Dis 2014; 73: 95–100.
  • 156. Song IH, Heldmann F, Rudwaleit M, Haibel H, Weiss A, Braun J, Sieper J. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011; 70: 1108–1110.
  • 157. Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewe R, Wordsworth P et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double- blind, placebo-controlled trial. Lancet 2013; 382: 1705–1713.
APA Sari I, öztürk m, Akkoç N (2015). Treatment of ankylosing spondylitis. , 416 - 430.
Chicago Sari Ismail,öztürk mehmet akif,Akkoç Nurullah Treatment of ankylosing spondylitis. (2015): 416 - 430.
MLA Sari Ismail,öztürk mehmet akif,Akkoç Nurullah Treatment of ankylosing spondylitis. , 2015, ss.416 - 430.
AMA Sari I,öztürk m,Akkoç N Treatment of ankylosing spondylitis. . 2015; 416 - 430.
Vancouver Sari I,öztürk m,Akkoç N Treatment of ankylosing spondylitis. . 2015; 416 - 430.
IEEE Sari I,öztürk m,Akkoç N "Treatment of ankylosing spondylitis." , ss.416 - 430, 2015.
ISNAD Sari, Ismail vd. "Treatment of ankylosing spondylitis". (2015), 416-430.
APA Sari I, öztürk m, Akkoç N (2015). Treatment of ankylosing spondylitis. Turkish Journal of Medical Sciences, 45(2), 416 - 430.
Chicago Sari Ismail,öztürk mehmet akif,Akkoç Nurullah Treatment of ankylosing spondylitis. Turkish Journal of Medical Sciences 45, no.2 (2015): 416 - 430.
MLA Sari Ismail,öztürk mehmet akif,Akkoç Nurullah Treatment of ankylosing spondylitis. Turkish Journal of Medical Sciences, vol.45, no.2, 2015, ss.416 - 430.
AMA Sari I,öztürk m,Akkoç N Treatment of ankylosing spondylitis. Turkish Journal of Medical Sciences. 2015; 45(2): 416 - 430.
Vancouver Sari I,öztürk m,Akkoç N Treatment of ankylosing spondylitis. Turkish Journal of Medical Sciences. 2015; 45(2): 416 - 430.
IEEE Sari I,öztürk m,Akkoç N "Treatment of ankylosing spondylitis." Turkish Journal of Medical Sciences, 45, ss.416 - 430, 2015.
ISNAD Sari, Ismail vd. "Treatment of ankylosing spondylitis". Turkish Journal of Medical Sciences 45/2 (2015), 416-430.
Sayfa Oluşturulma Tarihi
22-04-2024 21:2

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları